Health impact of E-cigarettes: a prospective 3.5-year study of regular daily users who have never smoked

Riccardo Polosa\textsuperscript{1,2,3}, Fabio Cibella\textsuperscript{4}, Pasquale Caponnetto\textsuperscript{1,3}, Marilena Maglia\textsuperscript{1,3}, Umberto Prosperini\textsuperscript{5}, Cristina Russo\textsuperscript{6} & Donald Tashkin\textsuperscript{7}

Although electronic cigarettes (ECs) are a much less harmful alternative to tobacco cigarettes, there is concern as to whether long-term ECs use may cause risks to human health. We report health outcomes (blood pressure, heart rate, body weight, lung function, respiratory symptoms, exhaled breath nitric oxide [eNO], exhaled carbon monoxide [eCO], and high-resolution computed tomography [HRCT] of the lungs) from a prospective 3.5-year observational study of a cohort of nine daily EC users (mean age 29.7 (±6.1) years) who have never smoked and a reference group of twelve never smokers. No significant changes could be detected over the observation period from baseline in the EC users or between EC users and control subjects in any of the health outcomes investigated. Moreover, no pathological findings could be identified on HRCT of the lungs and no respiratory symptoms were consistently reported in the EC user group. Although it cannot be excluded that some harm may occur at later stages, this study did not demonstrate any health concerns associated with long-term use of EC in relatively young users who did not also smoke tobacco.

Electronic cigarettes (ECs) are battery powered electronic devices. Puffing on an EC heats up an element (most commonly, a metal coil) that vaporizes a solution (e-liquid) mainly consisting of propylene glycol, vegetable glycercin, distilled water, and flavorings that may or may not contain liquid nicotine. The user inhales the aerosol generated by vaporizing the e-liquid in a process commonly referred to as “vaping”. ECs do not contain tobacco, do not create smoke and do not rely on combustion to operate. These consumer products have been rapidly gaining ground on conventional cigarettes among smokers due to the expectation of reducing/quitting smoking\textsuperscript{1–4}, the perception of being a less harmful alternative to cigarettes\textsuperscript{1–6}, competitive price\textsuperscript{7–9} and because they allow the smoker to continue having a “smoking experience without smoking”\textsuperscript{9–11}.

Although vapour toxicology under normal condition of use is less problematic than tobacco smoke\textsuperscript{12–14} and e-vapour products are estimated to be less harmful than combustible cigarettes\textsuperscript{15–17}, there is concern as to whether chronic exposure to their residual toxicological load may nevertheless carry a risk for lung health\textsuperscript{18–20}. Therefore, investigating the health impact of long term EC use is warranted.

Considering that inhalation is the exposure mechanism for EC use, the respiratory system is the primary target of any potential harmful effects of constituents in ECs aerosol emissions. No deterioration in lung function, airway responses, and respiratory symptoms could be observed in a 1-year prospective RCT of “healthy” smokers who were invited to quit or reduce their tobacco consumption by switching to ECs\textsuperscript{20,21}. Of note, FEF25–75% (a sensitive measure of obstruction in the more peripheral airways)\textsuperscript{20}, nitric oxide (a non-invasive biomarker of airway inflammation in airways disease, as well as in studies of environmental and occupational exposure)\textsuperscript{21} and

\textsuperscript{1}Centro per la Prevenzione e Cura del Tabagismo (CPCT), Azienda Ospedaliero-Universitaria "Policlinico-V. Emanuele", Università di Catania, Catania, Italy. \textsuperscript{2}Institute of Internal and Emergency Medicine, Azienda Ospedaliero-Universitaria "Policlinico-V. Emanuele", Università di Catania, Catania, Italy. \textsuperscript{3}Dipartimento di Medicina Clinica e Sperimentale, University of Catania, Catania, Italy. \textsuperscript{4}National Research Council of Italy, Institute of Biomedicine and Molecular Immunology, Palermo, Italy. \textsuperscript{5}Ospedale "San Vincenzo" - ASP Messina, Taormina, ME, Italy. \textsuperscript{6}MCAU ARNAS Garibaldi, Catania, Italy. \textsuperscript{7}David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Los Angeles, California, USA. Correspondence and requests for materials should be addressed to R.P. (email: polosa@unict.it)
carbon monoxide (a commonly used indicator of smoking abstinence that also reflects airway inflammation) in the exhaled breath returned to within normal limits\(^1\), with similar degree of normalization occurring in quitters who stopped using ECs as well as in quitters who were still using ECs. Overall, these preliminary studies do not appear to suggest negative respiratory health outcomes in smokers who have switched to ECs.

Nonetheless, very little is known about the long-term health effects of vaping. When investigating these health effects, it is important to consider that it is difficult (if not impossible) to disentangle responses driven by chronic exposure to EC aerosol emissions from those related to previous smoking history, unless one were to conduct studies on regular EC users who have never smoked. If EC aerosol emissions are much less harmful than tobacco smoke\(^2\-\(^5\), it can be hypothesized that long term vaping is less likely to cause significant harm to the respiratory system of regular daily EC users with no previous smoking history. This has never been formally tested in a research study.

Thus, aim of the study was to compare health outcomes between a cohort of daily EC users who have never smoked and a sample of never smokers and non-users of EC over a period of 3.5 years. Here we report findings from a prospective 3.5-year observational study comparing changes in health outcomes between a cohort of daily EC users who have never smoked and a reference group of never smokers and non-users of EC. Health outcomes included blood pressure (BP), heart rate (HR), body weight, lung function, respiratory symptoms, as well as exhaled biomarkers of airway inflammation (exhaled breath nitric oxide [eNO] and carbon monoxide [eCO]). EC users were also offered high-resolution computed tomography (HRCT) of the lungs at the end of follow-up to assess their risk for early signs of lung damage. This is the first study that has explored health effects of prolonged exposure to EC use in never smokers.

Methods

Participants and Study Design. Adult EC users (≥18 years old) were identified amongst a pool of regular Vape Shops customers. Vape shop owners who helped in a previous study\(^22\) were instructed to ask their regular clients a few questions about smoking history and EC use patterns. Customers who had never smoked or who reported having smoked less than 100 cigarettes in their lifetime were defined as never smokers\(^23\) and considered for inclusion. They also had to be daily EC users of ≥3 months. They were invited for a free medical check-up at the Centro per la Prevenzione e Cura del Tabagismo (CPCT) of the University of Catania. Age- and sex-matched non-smoking controls (and not using ECs) were selected from hospital staff and included as a reference (control) group. Subjects were recruited from June 2013 to September 2013 and data collection completed in March 2017. Participants came to the CPCT in the mornings for their check-up visits during which vital signs (blood pressure - BP, heart rate - HR, body weight) as well as measures of lung function, respiratory symptoms, and airway inflammation (eNO and eCO levels) were recorded. Details of EC-related products purchased (i.e. ECs hardware, e-liquid nicotine strengths and flavours) were also noted. Three additional follow-up visits were scheduled yearly for up to 3.5 years; follow-up visits 1 (F/up1), 2 (F/up2) and 3 (F/up3) were carried out at 12 (±1), 24 (±2) and 42 (±2) months after baseline visits, respectively. At F/up3, EC users were offered the additional option of undergoing lung HRCT. All these tests and measurements were carried out in accordance with relevant guidelines and regulations. University of Catania Ethics Review Board approved the study protocol and subjects gave informed consent prior to participation.

BP, HR, and Body Weight. After a 5-minute rest, BP and HR measurements were obtained by a semi-automated oscillometric sphygmomanometer (Smart Pressure, CA-MI Snc, Parma, Italy). Two measurements in the sitting position, spaced 1–2 min apart, were obtained at each visit. Measurements were taken in the morning, and participants were instructed not to vape or consume caffeinated drinks for at least 60 min prior to each visit. The average of two measurements was considered for analysis. Participants removed shoes and heavy clothing and were weighed at each visit by using a mechanical scale (Seca, Intermed Srl, San Giuliano Milanese, Italia).

Spirometry Procedure. A technician who was blinded to participants’ characteristics conducted spirometric tests according to American Thoracic Society/European Respiratory Society guidelines\(^24\). Prediction values for spirometric indices were the 2012 multi-ethnic reference values for spirometry for the 3–95-yr age range by Quanjer et al.\(^25\). Forced expiratory volume in one-second (FEV\(_1\)), forced vital capacity (FVC), and maximum mid-expiratory flow (FEF\(_{25-75}\%\)) were obtained using a PC-based electronic spirometer (Micro Medical Spiro USB ML2525 with Spida 5 Software; CareFusion, Sesto Fiorentino, Firenze, Italy). At least three forced expiratory maneuvers spaced 1–2 min apart were obtained with subjects sitting comfortably. Measurements were taken in the morning and participants were instructed not to vape for at least 60 min prior to each visit. The best FVC and FEV\(_1\) were retained and FEF\(_{25-75}\%\) was selected from the maneuver with the largest sum of FEV\(_1\) and FVC. For each subject, FEV\(_1\)/FVC was also computed. A respiratory physician experienced in pulmonary function testing (RP) reviewed spirometry results for quality control. Only technically acceptable tests were used for data analyses. Individual spiromgrams are “acceptable” if they are free from artefacts, they have good starts, they show satisfactory exhalation, as per well-defined criteria\(^24\).

Respiratory symptoms. Self-reported respiratory symptoms were verified at baseline and at each study follow-up visits by asking 4 yes/no questions:

1. For cough: “Have you had any cough in the previous 2-weeks?”
2. For wheeze: “Have you heard any wheeze when breathing?”
3. For shortness of breath: “Have you been short of breath in the previous 2-weeks?”
4. For tight chest: “Have you had difficulty in breathing like a sensation of pressure on your chest?”
FeNO measurements. Exhaled nitric oxide measurements (in ppb) were performed according to the American Thoracic Society/European Respiratory Society guidelines28 using a hand-held FeNO meter (NIOX Mino, Aerocrine AB, Sweden). Expiratory manoeuvres were performed in the morning with participants sitting comfortably. Participants were instructed not to vape for at least 60 min prior to each visit. Only technically acceptable tests were used for data analyses.

eCO measurements. Measurements (in ppm) were obtained from a single expiratory breath by using a hand-held eCO meter (Micro CO, Micro Medical Ltd, UK) according to the manufacturer’s recommendations. Expiratory manoeuvres were taken in the morning with participants sitting comfortably. Participants were instructed not to vape for at least 60 min prior to each visit.

Lung HRCT. HRCT scans were obtained with Toshiba Aquilion (Toshiba Medical Systems, Tokyo, Japan). A high-resolution algorithm was applied and 1-mm axial slices at 10-mm intervals from lung apices to bases were reconstructed. Subjects were scanned during suspended end-inspiration in the prone position without intravenous contrast material. An experienced radiologist who was blinded to participants’ characteristics evaluated the HRCT scans for presence or absence of pathologic signs.

Statistical Analyses. With a power of 80% and a type-I error (alpha) of 0.05 (5%), 7 subjects per group (14 in all) would be sufficient for detecting a change of 12% in FEV₁ (i.e., the minimal clinically important difference for FEV₁ according to ATS/ERS criteria). Our analysis, based on mean and SD of FEV₁ in Control (N = 12) and Pure Vapers (N = 9) groups, for a type-I error (alpha) of 0.05 (5%), produced a power of 6.7%.

Only data from subjects completing all four study visits were included in the analyses. Parametric data were expressed as mean (±standard deviation [SD]) while non-parametric data expressed as median (and interquartile range [IQR]). Possible between-group differences at baseline were evaluated using one-way Analysis of Variance and Mann-Whitney U-test for normally and not normally distributed continuous variables, respectively. Differences in frequency distribution of categorical variables were evaluated by χ² test. A Repeated Measures ANOVA model was used for evaluating changes in health effects indicators at different time points (4 time points: baseline, F/up 1, F/up 2, and F/up 3): health effects indicators were entered into the model as within factor for assessing changes with time, while the study group (EC users/Controls) was entered as between factor for evaluating its effect on possible changes. A p value of less than 0.05 was considered to indicate statistical significance. All analyses were performed with the Statistical Package for Social Science (SPSS for Windows version 20.0, Chicago, IL, USA).

Results

Participant Characteristics. A total of 16 [M 11; F 5; mean (±SD) age of 29.7 (±6.1) years] consecutive regular daily EC users of ≥3 months who had never smoked and 15 age- and sex-matched [M 10; F 5; mean (±SD) age of 32.5 (±7.0) years] non-smoking controls (and not using ECs) consented to participate and were included in the study. From the EC users, four were lost to follow-up (no shows) and three were excluded, as they did not comply with inclusion criteria on review (two stopped vaping and one began vaping only sporadically). From the reference group, one was lost to follow-up (the subject moved to another city) and two were excluded, as they did not comply with inclusion criteria on review (both started tobacco smoking). Complete datasets were available from 9 EC users and 12 control subjects; their characteristics at baseline were not significantly different (with the exception of HR) and are presented in Table 1.

Six of the nine EC users were consuming nicotine-containing e-liquid at baseline as well as by the end of study, although at a lower strength. Three have been consuming zero-nicotine strength e-liquid throughout consistently the 3.5 years follow-up. Also consistent over time was the consumption of preferred flavours (i.e. tobacco flavours). Some participants switched from standard refills (i.e. assorted EGO style products) to more advanced refillable devices (including Provarи, Innokin, Joyetech eVIC, Avatar Puff).

BP, HR, and Body Weight. Changes in systolic BP, diastolic BP, HR and body weight from baseline and between study groups are shown in Table 2. No significant changes from baseline were observed at any follow-up study visits in the EC group. No significant difference was found between EC users and control subjects. Because of the small sample size, we checked all individual datasets one by one to detect signs of negative changes and found no such changes (even among EC users consuming nicotine-containing e-liquids).

Lung Function. Changes in FEV₁, FVC, %FEV₁/FVC and FEF25–75 from baseline and between study groups are shown in Table 2 and Fig. 1. No significant change from baseline was observed over the 3.5-years observation period in the EC group (Fig. 1, panels A–D). No significant difference was found between EC users and control subjects. None of the lung function variables showed a significant between-group (i.e., EC users/Controls) effect (Table 2; Fig. 1, panels A–D). Again, because of the small sample size, we checked all individual datasets one by one to detect signs of negative changes and found no such changes, even among those with the highest e-liquid consumption (5 ml/day) and longest vaping hx (57 months).

Respiratory Symptoms. None of the participants in this study reported any wheezing, shortness of breath, or chest tightness. Cough was reported by one EC user at baseline and by another at F/up2. In the control group, three participants reported cough on three separate occasions. Of note, study participants reported no severe adverse reactions.

FeNO and eCO measurements. Changes in FeNo and eCO from baseline and between study groups are shown in Table 2. No significant change from baseline was observed over the 3.5-years observation period in the EC group (Fig. 2, panels A,B). No significant difference was found between EC users and control subjects.
Repeated Measures ANOVA showed that no between-group (i.e., EC users/Controls) effect in either FeNO or eCO (Table 2; Fig. 2, panels A,B). As with the other outcomes note above, we checked all individual datasets one by one to detect signs of negative changes and found no such changes, even among those with the highest e-liquid consumption and longest vaping hx.

Lung HRCT. HRCT scans were obtained in 8/9 EC users (one had claustrophobia and refused undergoing scanning). Visual assessment of the HRCT scans showed no pathological findings. In particular, no CT features compatible with early signs of COPD (i.e. parenchymal micronodules, ground-glass opacity, or macroscopic emphysema) or lipoid pneumonia or popcorn lung disease were present. Of note, no early pathological signs were observed in subjects with the highest e-liquid consumption (i.e. 5 mls/day) and longest overall vaping hx.

Discussion

This small study, the first of its kind to date, found no detectable changes in lung health in never smokers who have been regularly vaping for at least 4 years. Daily exposure to ECs aerosol emissions caused no significant changes in any of the health outcomes investigated, including measures of lung function and lung inflammation. Moreover, no significant structural abnormalities could be identified on HRCT of the lungs and no respiratory symptoms were consistently reported. In spite of the small sample size and lack of comparison to smokers, careful examination of long-term health effects of EC use in a rare cohort of regular daily users who have never smoked in their life may contribute to the current understanding of the potential health risks associated with EC use.

Six of the nine EC users who completed the study were still consuming nicotine-containing e-liquids as reported on their last visit. Tobacco combustion products, not nicotine, cause most of the adverse health effects of smoking. However, there is concern that some adverse cardiovascular effects may be related to nicotine per se due to its ability to cause hemodynamic changes (increase in heart rate, a transient rise in blood pressure, vasoconstriction of coronary and other vascular beds), adverse effects on lipids and induction of insulin resistance. In this study, no significant changes in systolic BP, diastolic BP or HR were observed in the EC user group throughout the study. Moreover, no notable individual changes were observed in any of the vapers consuming nicotine-containing e-liquids. Thus, consumption of low dose nicotine did not seem to have significant adverse cardiovascular effects, as shown in recent EC studies of healthy smokers and smokers with arterial hypertension. Also, the latest US Surgeon General’s report that examined harm from tobacco and nicotine has concluded that although it may adversely affect foetus and adolescent brain development – nicotine does not contribute to smoking-related diseases.
19.000 smokers who switched to vaping1. In those diagnosed with asthma (n = 1173) or COPD (n = 1062) improvement in respiratory symptoms after switching was reported in 65.4% and in 75.7% of the respondents, respectively. Worsening after switching was reported only in 1.1% of the asthmatics and 0.8% of the respondents with COPD.

Long-term studies in healthy smokers20,21 and smokers with asthma and COPD37,38 switching to EC use have shown not only no clinically significant adverse respiratory effects, but, to the contrary, a mitigation of the harmful effects of smoked tobacco on the lung.

In addition, substantial improvement in respiratory symptoms has been reported in a large internet survey of 19.000 smokers who switched to vaping1. In those diagnosed with asthma (n = 1173) or COPD (n = 1062) improvement in respiratory symptoms after switching was reported in 65.4% and in 75.7% of the respondents, respectively. Worsening after switching was reported only in 1.1% of the asthmatics and 0.8% of the respondents with COPD.

Long-term studies in healthy smokers20,21 and smokers with asthma and COPD37,38 switching to EC use have shown not only no clinically significant adverse respiratory effects, but, to the contrary, a mitigation of the harmful effects of smoked tobacco on the lung.

Table 2. Changes in health effect indicators at each follow-up visit, separately for EC users and control subjects.

| Health effect indicator | Baseline | F/up 1 | F/up 2 | F/up 3 | Between effect p value |
|-------------------------|----------|--------|--------|--------|-----------------------|
| FEV\(_1\), (l, mean ± SD) | EC users | 3.82 ± 0.78 | 3.81 ± 0.78 | 3.78 ± 0.71 | 3.87 ± 0.76 | 0.30 |
|                         | Control subjects | 4.08 ± 0.30 | 4.06 ± 0.28 | 4.03 ± 0.26 | 4.11 ± 0.30 |
| FVC (l, mean ± SD) | EC users | 4.93 ± 0.95 | 4.80 ± 0.82 | 4.82 ± 0.91 | 4.87 ± 0.83 | 0.61 |
|                         | Control subjects | 5.03 ± 0.48 | 4.97 ± 0.42 | 5.01 ± 0.45 | 5.02 ± 0.42 |
| FEV\(_1\)/FVC (%), mean ± SD | EC users | 78.49 ± 3.46 | 79.01 ± 3.63 | 78.46 ± 2.34 | 79.08 ± 2.83 | 0.09 |
|                         | Control subjects | 81.45 ± 5.03 | 82.02 ± 4.67 | 80.86 ± 6.18 | 82.06 ± 4.25 |
| FEV\(_1\)-75L, (l/min, mean ± SD) | EC users | 3.29 ± 0.70 | 3.29 ± 0.60 | 3.30 ± 0.75 | 3.33 ± 0.64 | 0.36 |
|                         | Control subjects | 3.43 ± 0.64 | 3.49 ± 0.61 | 3.53 ± 0.57 | 3.56 ± 0.58 |
| Weight (kg, mean ± SD) | EC users | 71.3 ± 11.2 | 72.9 ± 11.5 | 73.3 ± 11.4 | 72.3 ± 11.2 | 0.95 |
|                         | Control subjects | 72.9 ± 11.8 | 74.0 ± 12.1 | 73.2 ± 12.3 | 73.6 ± 11.8 |
| Systolic blood pressure (mmHg, mean ± SD) | EC users | 115 ± 9 | 116 ± 5 | 114 ± 9 | 118 ± 10 | 0.82 |
|                         | Control subjects | 117 ± 9 | 116 ± 10 | 116 ± 10 | 116 ± 9 |
| Diastolic blood pressure (mmHg, mean ± SD) | EC users | 79 ± 6 | 78 ± 4 | 73 ± 9 | 76 ± 8 | 0.50 |
|                         | Control subjects | 74 ± 9 | 76 ± 6 | 75 ± 9 | 73 ± 9 |
| Heart rate (beats/min, mean ± SD) | EC users | 72 ± 7 | 71 ± 9 | 71 ± 9 | 71 ± 7 | 0.15 |
|                         | Control subjects | 79 ± 9 | 78 ± 8 | 76 ± 8 | 78 ± 9 |
| eCO (ppm, median and IQR range) | EC users | 5.0 [3.5–7.3] | 4.0 [2.8–6.0] | 3.0 [3.0–5.8] | 4.0 [2.8–6.3] | 0.21 |
|                         | Control subjects | 4.0 [3.5–7.5] | 5.5 [4.0–6.5] | 7.0 [3.5–8.0] | 5.0 [5.5–6.0] |
| FeNO (ppb, median and IQR range) | EC users | 11.4 [7.6–25.7] | 19.7 [17.2–22.3] | 18.9 [18.2–24.7] | 20.0 [18.2–22.7] | 0.89 |
|                         | Control subjects | 18.6 [16.0–25.1] | 19.4 [16.0–25.1] | 18.7 [16.9–22.0] | 20.0 [16.2–23.4] |

Given that particle size in ECs aerosols is well within the respiratory range31,32, these particles can penetrate deeply within the lungs; therefore the concern that long-term exposure to ECs aerosol emissions may carry some health risk is reasonable33,34,35. However, in this study no significant changes in lung function, respiratory symptoms, FeNO or eCO measurements were found. Furthermore, no noticeable individual changes were observed in any of the vapers including those with the most significant exposure history. Some acute EC trials in healthy smokers have reported transient changes in respiratory effects35,36, but others have not confirmed these observations37,38. Long-term studies in healthy smokers20,21 and smokers with asthma and COPD37,38 switching to EC use have shown not only no clinically significant adverse respiratory effects, but, to the contrary, a mitigation of the harmful effects of smoked tobacco on the lung.
The very small sample size minimizes the power to show both prevalent abnormalities at baseline and statistically significant changes from baseline over time. Nonetheless, it must be recognized that vapers who have never smoked are a very uncommon sub-population of ECs users; the 2014 Eurobarometer survey found about 0.1% of daily EC use in never smokers. Hence, we were fortunate enough to recruit into the study such a carefully selected rare population of great importance to address the potential absolute risk of long term exposure to EC aerosol emissions disentangled from the effects of concomitant or former tobacco cigarette smoking. However, there is evidence of significant spirometry changes relatively early after initiation of smoking, even when analysing very small samples - as low as 13 smokers. In any case, careful examination of the individual data on a case-by-case basis revealed no impairment in the health measures evaluated in any of the EC users in the study.

Another limitation is that the sample of relatively young subjects studied (mean age 27–28 years), who had had a generally short duration of regular EC use prior to entering the study (on average 8 months) and vaporized, on average, only a modest amount of e-liquid (about 4 ml/die), may not be representative of the general

---

**Figure 1.** (A–D) Time trends (means ± SD) of FEV1 (panel A), FVC (panel B), FEV1/FVC (panel C) and FEF25–75 (panel D) at baseline (BL), and at follow-up visits at year-1 (F/up 1), year-2 (F/up 2) and year 3,5 (F/up 3), separately for daily EC users who have never smoked (blu lines) and controls (red lines).

**Figure 2.** (A–B) Box-plot representation of time trends of exhaled nitric oxide (panel A) and exhaled carbon monoxide (panel B) at baseline (BL), and at follow-up visits at year-1 (F/up 1), year-2 (F/up 2) and year 3,5 (F/up 3), separately for daily EC users who have never smoked (red boxes) and controls (blu boxes). Median values are shown as horizontal bars.
population of EC users who never smoked. Consequently, firm conclusions cannot be drawn from the results and additional studies in a larger and more diverse group of EC users are needed. On the other hand, vapers who have never smoked are likely to be relatively young.

A related weakness is that since the age of our subjects was, on average, only in the mid-twenties, the normal age-related decline in lung function may not have yet commenced, thus making it more difficult to show accelerated declines in response to any EC-related lung injury. Also, since duration and intensity of smoking are significant predictors of lung function decline among regular cigarette smokers, the generally short duration and small amount of EC use by the vapers whom we studied may not have been sufficient to result in detectable lung damage. In any case, these deficiencies may guide other researchers to improve the design of similar studies.

Although no deterioration in lung health was detected during the 3.5 years follow-up, one could argue that no significant changes would have been detected among young healthy smokers during such a period as well. Comparison with a reference group of young smokers would have helped the interpretation of the results in EC users, thus making problematic to establish whether ECs are harmless or even less harmful than conventional cigarettes. Data documenting the effects of smoking on the lung over the first few years following initiation of smoking are limited. Tashkin and coll found that, over the five years between two visits at which spirometry was performed, those who initiated the smoking habit sometime during these 5 years (possibly, 2.5 years on average) had a relatively greater “negative” change in spirometric indices compared to those who never initiated the smoking habit. Niewoehner and coll found pathologic changes of the same small airways in autopsy young cigarette smokers who had died accidentally in motor vehicle accidents, indicating evidence of the harmful effects of smoking on the lung relatively early after initiation of smoking.

Another shortcoming is that HRCT scans were performed only at TLC, so that air-trapping (a sensitive measure of early lung damage in smokers with normal spirometry) could not be assessed.

Summary and Conclusions
In a small sample of young-adult never-smoking, daily EC users who were carefully followed for approximately 3 years, we found no decrements in spirometric indices, development of respiratory symptoms, changes in markers of lung inflammation in exhaled air or findings of early lung damage on HRCT, when compared with a carefully matched group of never-smoking non-EC users. Even the heaviest EC users failed to exhibit any evidence of emerging lung injury as reflected in these physiologic, clinical or inflammatory measures. Moreover, no changes were noted in blood pressure or heart rate. Since the EC users who we studied were never smokers, potential confounding by inhalation of combustion products of tobacco were obviated.

While the sample size was small, the results of this study may provide some preliminary evidence that long-term use of ECs is unlikely to raise significant health concerns in relatively young users. Further studies in a larger sample of EC users with and without a history of tobacco smoking are warranted.

References
1. Farsalinos, K. E., Romagna, G., Tsaiapras, D., Kyrzopoulos, S. & Voudris, V. Characteristics, perceived side effects and benefits of electronic cigarette use: a worldwide survey of more than 19,000 consumers. Int. J. Environ. Res. Public Health 11, 4356–73 (2014).
2. Biener, L. & Hargraves, J. L. A Longitudinal Study of Electronic Cigarette Use Among a Population-Based Sample of Adult Smokers: Association With Smoking Cessation and Motivation to Quit. Nicotine Tob. Res. 17, 127–133 (2015).
3. Gallus, S. et al. E-Cigarette Awareness, Use, and Harm Perceptions in Italy: A National Representative Survey. Nicotine Tob. Res. 16, 1541–1548 (2014).
4. Pechacek, T. F., Nayak, P., Gregory, K. R., Weaver, S. R. & Eriksen, M. P. The Potential That Electronic Nicotine Delivery Systems Can be a Disruptive Technology: Results From a National Survey. Nicotine Tob. Res. 18, 1989–1997 (2016).
5. Pearson, J. L., Richardson, A., Niaura, R. S., Vallone, D. M. & Abrams, D. B. E-Cigarette Awareness, Use, and Harm Perceptions in US Adults. Am. J. Public Health 102, 1758–1766 (2012).
6. Breske, L. S., Brown, J., Hitchman, S. C. & McNeill, A. Perceived relative harm of electronic cigarettes over time and impact on subsequent use. A survey with 1-year and 2-year follow-ups. Drug Alcohol Depend. 157, 106–11 (2015).
7. Wagoner, K. G. et al. E-cigarettes, Hookah Pens and Vapes: Adolescent and Young Adult Perceptions of Electronic Nicotine Delivery Systems: Table 1. Nicotine Tob. Res. 18, 2006–2012 (2016).
8. Patel, D. et al. Reasons for current E-cigarette use among U.S. adults. Prev. Med. (Baltim). 93, 14–20 (2016).
9. ASH Action on Smoking and Health. Use of electronic cigarettes (vapourisers) among adults in Great Britain | Action on Smoking and Health. May (2017). Available at: http://ash.org.uk/information-and-resources/fact-sheets/use-of-electronic-cigarettes-vapourisers-among-adults-in-great-britain/ (Accessed: 11th August 2017).
10. Kistler, C. et al. Consumer’s Preferences for Electronic Nicotine Delivery System Product Features: A Structured Content Analysis. Int. J. Environ. Res. Public Health 14, 613 (2017).
11. Soule, E. K., Maloney, S. F., Guy, M. C., Eisenberg, T. & Fagan, P. User identified positive outcome expectancies of electronic cigarette use: A concept mapping study. Psychol. Addict. Behav. 31, 343–353 (2017).
12. Farsalinos, K. E. & Polosa, R. Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Ther. Adv. drug Saf. 5, 67–86 (2014).
13. Goniewicz, M. L. et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob. Control 23, 133–9 (2014).
14. Margham, J. et al. Chemical Composition of Aerosol from an E-Cigarette: A Quantitative Comparison with Cigarette Smoke. Chem. Res. Toxicol. 29, 1662–1678 (2016).
15. Nutt, D. J. et al. Estimating the Harms of Nicotine-Containing Products Using the MCDA Approach. Eur. Addict. Res. 20, 218–225 (2014).
16. McNeill, A., Is, B., Calder, R. & Sc, H. E-cigarettes: an evidence update A report commissioned by Public Health England. (2015).
17. Royal College of Physicians. Nicotine without smoke: Tobacco harm reduction | RCP London. RCP London (2016). Available at: https://www.rcplondon.ac.uk/projects/outputs/nicotine-without-smoke-tobacco-harm-reduction-0 (Accessed: 11th August 2017).
18. Dinakar, C. Health Effects of Electronic Cigarettes. N. Engl. J. Med. 375, 1372–1381 (2016).
19. Polosa, R. Electronic cigarette use and harm reversal: emerging evidence in the lung. BMC Med. 13, 54 (2015).
20. Cibella, F. et al. Lung function and respiratory symptoms in a randomized smoking cessation trial of electronic cigarettes. Clin. Sci. 130, 1929–1937 (2016).
21. Campagna, D. et al. Changes in breathomics from a 1-year randomized smoking cessation trial of electronic cigarettes. *Eur. J. Clin. Invest.* **46**, 698–706 (2016).

22. Polosa, R., Caponnetto, P., Cibella, F. & Le-Houezec, J. Quit and smoking reduction rates in vape shop consumers: a prospective 12-month survey. *Int. J. Environ. Res. Public Health* **12**, 3428–38 (2015).

23. Centers for Disease Control and Prevention. State-Specific Secondhand Smoke Exposure and Current Cigarette Smoking Among Adults—United States, 2008. *MMWR Morb. Mortal. Wkly Rep.* **58**, 1232–5 (2009).

24. Miller, M. R. et al. Standardisation of spirometry. *Eur. Respir. J.* **26**, 319–338 (2005).

25. Quanjer, P. H. et al. Multi-ethnic reference values for spirometry for the 3–95 yr age range: the global lung function 2012 equations. *Eur. Respir. J.* **40**, 1324–1342 (2012).

26. American Thoracic Society & European Respiratory Society. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005. *Am. J. Respir. Crit. Care Med.* **171**, 912–930 (2005).

27. United States. Public Health Service. Office of the Surgeon General. *How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the Surgeon General*. (U.S. Dept. of Health and Human Services, Public Health Service, Office of the Surgeon General, 2010).

28. Farsalinos, K. et al. Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to electronic cigarettes. *Intern. Emerg. Med.* **11**, 85–94 (2016).

29. Polosa, R. et al. Blood Pressure Control in Smokers with Arterial Hypertension Who Switched to Electronic Cigarettes. *Int. J. Environ. Res. Public Health* **13**, 1123 (2016).

30. Department of Health, U. et al. *E-Cigarette Use Among Youth and Young Adults: A Report of the Surgeon General*. (U.S. Dept. of Health and Human Services, Public Health Service, Office of the Surgeon General, 2016).

31. Sosnowski, T. R. & Kramek-Romanowska, K. Predicted Deposition of E-Cigarette Aerosol in the Human Lungs. *J. Aerosol Med. Pulm. Drug Deliv.* **29**, 299–309 (2016).

32. Mikhail, V. B., Brinkman, M. C., Granville, C. A., Gordon, S. M. & Clark, P. I. Real-Time Measurement of Electronic Cigarette Aerosol Size Distribution and Metals Content Analysis. *Nicotine Tob. Res.* **18**, 1895–1902 (2016).

33. Rowell, T. R. & Tarran, R. Will chronic e-cigarette use cause lung disease? *Am. J. Physiol. - Lung Cell. Mol. Physiol.* **309**, L1398–14109 (2015).

34. Vardavas, C. I. et al. Short-term Pulmonary Effects of Using an Electronic Cigarette. *Chest* **141**, 1400–1406 (2012).

35. Flouriis, A. D. et al. Acute impact of active and passive electronic cigarette smoking on serum cotinine and lung function. *Inhal. Toxicol.* **25**, 91–101 (2013).

36. Ferrari, M. et al. Short-term effects of a nicotine-free e-cigarette compared to a traditional cigarette in smokers and non-smokers. *BMJ Pulm. Med.* **15**, 120 (2013).

37. Polosa, R. et al. Persistent long term benefits of smoking abstinence and reduction in asthmatic smokers who have switched to electronic cigarettes. *Discof. Med.* **21**, 99–108 (2016).

38. Polosa, R. et al. Evidence for harm reduction in COPD smokers who switch to electronic cigarettes. *Respir. Res.* **17**, 166 (2016).

39. Hoffman, E. A., Simon, B. A. & McLennan, G. State of the Art. A structural and functional assessment of the lung via multidetector-whisker computed tomography: phenotyping chronic obstructive pulmonary disease. *Proc. Am. Thorac. Soc. 3*, 519–32 (2006).

40. Remy-Jardin, M., Remy, J., Gosselin, B., Becette, V. & Edme, J. L. Lung parenchymal changes secondary to cigarette smoking: pathologic-CT correlations. *Radiology* **186**, 643–651 (1993).

41. Dharwal, J. et al. Smoking Cessation in COPD Causes a Transient Improvement in Spirometry and Decreases Micronodules on High-Resolution CT Imaging. *Chest* **145**, 1006–1015 (2014).

42. Regan, E. A. et al. Clinical and Radiologic Disease in Smokers With Normal Spirometry. *JAMA Intern. Med.* **175**, 1553 (2015).

43. Akpinar-Elici, M., Travis, W. D. J., Lynch, D. A. & Kreiss, K. Bronchiolitis obliterans syndrome in popcorn production plant workers. *Eur. Respir. J.* **24**, 298–302 (2004).

44. van Rooy, E. G. B. G. J. et al. Bronchiolitis obliterans syndrome in chemical workers producing diacetyl for food flavorings. *Am. J. Respir. Crit. Care Med.* **176**, 498–504 (2007).

45. Farsalinos, K. E., Kistler, K. A., Gillman, G. & Voudris, V. Evaluation of electronic cigarette liquids and aerosol for the presence of selected inhalation toxins. *Nicotine Tob. Res.* **17**, 168–74 (2015).

46. Allen, J. G. et al. Flavoring Chemicals in E-Cigarettes: Diacetyl, 2,3-Pentanedione, and Acetoin in a Sample of 51 Products, Including Fruit-, Candy-, and Cocktail-Flavored E-Cigarettes. *Environ. Health Perspect.* **124**, 733–9 (2015).

47. Ettner, J.-F. Gateway effects and electronic cigarettes. *Addiction.* https://doi.org/10.1111/add.13924 (2017).

48. Farsalinos, K. E., Pouls, K., Voudris, V. & Le Houezec, J. Prevalence and correlates of current daily use of electronic cigarettes in the European Union: analysis of the 2014 Eurobarometer survey. *Intern. Emerg. Med.* https://doi.org/10.1007/s11739-017-1643-7 (2017).

49. Tashkin, D. P. et al. Comparison of Lung Function in Young Nonsmokers and Smokers Before and After Initiation of the Smoking Habit. *Am. Rev. Respir. Dis.* **128**, 16–83 (1983).

50. Kohansal, R., Soriano, J. B. & Agusti, A. Investigating the natural history of lung function: facts, pitfalls, and opportunities. *Chest* **135**, 1330–1341 (2009).

51. SCANLON, P. D. et al. Smoking Cessation and Lung Function in Mild-to-Moderate Chronic Obstructive Pulmonary Disease. *Am. J. Respir. Crit. Care Med.* **161**, 381–390 (2000).

52. Niewoehner, D. E., Kleinerman, J. & Rice, D. B. Pathologic Changes in the Peripheral Airways of Young Cigarette Smokers. *N. Engl. J. Med.* **291**, 755–758 (1974).

53. Woodruff, P. G. et al. Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. *N. Engl. J. Med.* **374**, 1811–1821 (2016).

Acknowledgements
Authors wish to thank the local participating Vape Shops and the study participants for all their time and effort. The authors also thank Dr. G. Caputo for his help with HRCT assessments. This research was supported by Catania University grant no. 21040100 of “Ricerca Scientifica Finanziata dall’Ateneo di Catania”.

Author Contributions
R.P., F.C., C.R., and P.C. conceived and designed the experiments. P.C., C.R., and M.M. contributed to participants recruitment, P.C., C.R., M.M., and U.P. performed the tests. F.C., R.P., and D.T. analyzed and interpreted the data. R.P., F.C., P.C., and D.T. wrote the paper.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-14043-2.

Competing Interests: R.P. is full-time employee of the University of Catania, Italy. In relation to his work in the area of tobacco control, R.P. has received lecture fees and research funding from Pfizer and GlaxoSmithKline.
manufacturers of stop smoking medications. He has also served as a consultant for Pfizer, Global Health Alliance for treatment of tobacco dependence, ECITA (Electronic Cigarette Industry Trade Association, in the UK) and Health Diplomat (consulting company that delivers solutions to global health problems with special emphasis on harm minimization). Lectures fees from a number of European electronic cigarette industry and trade associations (including FIVAPE in France and FIESEL in Italy) were directly donated to vaper advocacy no-profit organizations. He is currently scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti Smoking League) and Head of the European Technical Committee for standardization on “Requirements and test methods for emissions of electronic cigarettes” (CEN/TC 437; WG4). F.C. is full-time employee of the National Research of Italy, Institute of Biomedicine and Molecular Immunology, Palermo. P.C. is full-time employee of the University of Catania and has no relevant conflict of interest. M.M. is part-time employee of the Teaching Hospital of the University of Catania and has no relevant conflict of interest. U.P. is full-time employee of the ASP Messina (Ospedale “San Vincenzo” - Taormina, Italy) and has no relevant conflict of interest. D.T. is a part-time employee of the University of California, Los Angeles (UCLA), and has no relevant conflict of interest outside of his employment at UCLA.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2017